Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Código QR

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Wang Yang, Naifei Chen, Lingyu Li, Xiao Chen, Xiangliang Liu, Yongfei Zhang, Jiuwei Cui The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, People’s Republic of ChinaCorrespondence: Jiuwei Cui Tel +86 431-8878-2178Fax +86-0431-88786134Email cuijw@jlu.edu.c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	epidermal growth factor receptor (egfr) mutation tumor mutation burden (tmb) immune checkpoint inhibitor (ici) lung adenocarcinoma (luad). Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4a6b99e8049947aca2306b8e593e3bcc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
por: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Publicado: (2021)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius B, et al.
Publicado: (2016)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
por: Syahruddin E, et al.
Publicado: (2018)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
por: Elli Narvi, et al.
Publicado: (2018)

Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
por: Laveniya Satgunaseelan, et al.
Publicado: (2021)

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
por: Xinqing Lin, et al.
Publicado: (2021)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Kazutaka Fujita, et al.
Publicado: (2021)

Molecular Characterization of the Clinical and Tumor Immune Microenvironment Signature of 5-methylcytosine-Related Regulators in non-small Cell Lung Cancer
por: Taisheng Liu, et al.
Publicado: (2021)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
por: Zhe Gong, et al.
Publicado: (2021)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

<i>CSMD1</i> Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer
por: Taobi Huang, et al.
Publicado: (2021)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
por: Yang Wang, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines
por: Li-Han Lin, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Ying-Peng Peng, et al.
Publicado: (2021)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

uvsZ1 mutation shows epistatic relations with uvsD153 and uvsJ1 mutations without any involvement with checkpoint control in Aspergillus nidulans
por: BAPTISTA,FRANCIELLE, et al.
Publicado: (2002)

Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
por: Wang X, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study
por: Katrine Fjaellegaard, et al.
Publicado: (2021)

Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas
por: Xing Jin, et al.
Publicado: (2021)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
por: Alessandro Pancrazzi, et al.
Publicado: (2021)

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka M, et al.
Publicado: (2019)

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies
por: Gkiala A, et al.
Publicado: (2020)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
por: Ling-Ling Kong, et al.
Publicado: (2017)

m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia
por: Ashuai Du, et al.
Publicado: (2021)

Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
por: Na Li, et al.
Publicado: (2021)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Zhihao Lu, et al.
Publicado: (2021)

CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients
por: Lu N, et al.
Publicado: (2021)